Embedded Files
Recombinant Human Galectin 8, variant 1, His Tag (317 a.a.)
last updated: Oct 28, 2025
Key features
Key features
Expression system: Escherichia coli
Purity: > 90% SDS-PAGE
Active: Yes
Tags: His tag N-Terminus
Validated for: Flow Cytometry Analysis, Agglutination, T Cell Activation
Description
Description
Synonyms
LGALS8, Galectin-8, Gal-8, Po66 carbohydrate-binding protein, Po66-CBP, Prostate carcinoma tumor antigen 1, PCTA-1
Source
Escherichia coli-derived human Galectin 8 protein, variant 1
Expression host
Escherichia coli
Sequence
Met1-Trp317
Accession
Molecular weight
37 kDa
Tag
N-terminus His-tag
Properties
Properties
Purity
> 90% as determined by reducing SDS-PAGE.
Endotoxin level
< 1 EU/μg determined by the LAL method
Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months, -20 to -70 °C in lyophilized state.
- 1 week, 2 to 8 °C under sterile conditions after reconstitution.
Shipping
This product is shipped with dry ice.
Formulation
Lyophilized from filtered PBS pH 7.4, supplemented with 5% sucrose and 1 mM DTT.
Reconstitution
Reconstitute at 500 μg/mL in sterile deionized water.
Activity validation
Measured by its ability to interact with fixed Jurkat cells using a concentration of 2.0 or 25 μg/mL.
Bioactivities validated by GlycoGenetics, Inc.
Bioactivities validated by GlycoGenetics, Inc.
Cell binding by flow cytometry
Cell binding by flow cytometry
Gal 8-1 demonstrates dose-dependent binding to fixed K562 cells within the 0-12 μg/mL concentration range, as determined by flow cytometry.
Cell agglutination
Cell agglutination
Gal 8-1 causes agglutination of fixed K562 cells at higher concentrations.
T cell activation
T cell activation
Gal 8-1 induces early-stage (CD69) and mid-stage (IL-2) activation of Jurkat cells at at 25 μg/mL.
Page updated
Google Sites
Report abuse